Skip to main content
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc. — Investor Relations & Filings

Ticker · WHWK ISIN · US00032Q1040 LEI · 549300G3U7TKW1M58L09 US Professional, scientific and technical activities
Open in API
Filings indexed 516 across all filing types
Latest filing 2017-12-18 Board/Management Inform…
Country US United States of America
Listing US WHWK

About Whitehawk Therapeutics, Inc.

https://ir.whitehawktx.com/

Whitehawk Therapeutics, Inc. is a preclinical-stage oncology company focused on developing advanced antibody-drug conjugate (ADC) therapies. The company applies next-wave platform technologies to established tumor biology to create treatments for difficult-to-treat cancers. Its portfolio features three ADC assets, which are engineered to overcome the limitations of first-generation predecessors through improved tumor targeting and clinical strategies. These assets are in-licensed from WuXi Biologics under an exclusive agreement for global development and commercialization.

Recent filings

Filing Released Lang Actions
424B3 Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed pursuant to the Securities Exchange Act of 1934. It includes announcements about the appointment of a new director and CEO, and the approval of an amended and restated employee stock purchase plan (ESPP) by the board. The document contains detailed information about the ESPP plan terms and administration. There are no financial statements or quarterly/yearly financial results presented. The primary content is management and board changes and a capital-related plan approval. This fits best under Board/Management Information (MANG) because it announces changes in senior management and board appointments, as well as board-approved stock plans. It is not a full financial report, earnings release, or capital financing update. The document length and detail exclude it from being a simple announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2017-12-18 English
8-K Filing
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 14, 2017. It announces the appointment of a new director and CEO, Stephen Hoffman, and the approval of an amended and restated Employee Stock Purchase Plan by the Board. The content focuses on management changes and corporate governance matters rather than financial results or detailed financial statements. The key section is Item 5.02, which relates to departure and appointment of directors and officers. Therefore, this document fits best under Board/Management Information (MANG). The document length is 4608 characters, which is sufficient to contain substantive information rather than a brief announcement. Hence, the classification is MANG with high confidence.
2017-12-18 English
3 Filing
Director's Dealing
2017-12-06 English
3 Filing
Director's Dealing
2017-11-16 English
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content specifically details the appointment of a new Chief Financial Officer, Michael Rogers, including his employment agreement and terms. This fits the category of announcements related to changes in the company's board of directors or senior management. The document is not a full financial report, earnings release, or other types of filings. Therefore, it is best classified as Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2017-11-14 English
424B3 Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated November 14, 2017, reporting the appointment of Michael Rogers as Chief Financial Officer of Aerpio Pharmaceuticals, Inc. It includes detailed information about his employment agreement, compensation, and terms of employment. The document is not a full financial report, earnings release, or regulatory certification, but rather an announcement of a management change. The key section is Item 5.02, which covers departure and appointment of directors or officers. Therefore, this filing fits the category of Board/Management Information (MANG). The document length and content confirm it is not a brief announcement or a proxy statement but a detailed management change report.
2017-11-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.